In a Phase IIb trial, hospitalised COVID-19 patients treated with desidustat did not develop acute respiratory distress syndrome (ARDS).
List view / Grid view
Filter the results
Through COVAX, doses of the Pfizer-BioNTech vaccine will be provided at a not-for-profit price for 92 low- and lower-middle-income countries.
Following Phase I results, Merck will discontinue its development of V590 and V591, two COVID-19 vaccine candidates.
Interim data from 1,000 hospitalised patients with moderate COVID-19 symptoms shows that full doses of heparin can improve patient outcomes and could reduce ICU burden.
Reports have said five people have been killed in a fire at the Serum Institute of India, where the Oxford-AstraZeneca COVID-19 vaccine is being made.
The President of the US, Joe Biden, has written a letter to the UN announcing his intention for the country to remain a part of the WHO.
Research has demonstrated that the Pfizer and BioNTech COVID-19 vaccine can neutralise the B.1.1.7 variant in pre-clinical studies.
The trial will primarily assess whether alisporivir (Debio 025) can significantly reduce COVID-19 viral load in hospitalised COVID-19 patients with moderate symptoms.
New research has said that clinical microbiology is critical to understanding COVID-19, with laboratories studying the coronavirus globally.
An interim analysis of Phase I/II trial data shows 90 percent of 18-55 year olds had a neutralising antibody response that lasts at least two months.
The rapid blood test could be used to identify hospitalised COVID-19 patients who may benefit from investigational treatments and early interventions.
Around 2,000 workers critical to the UK COVID-19 vaccine supply chain will be offered inoculations against the novel coronavirus.
A new report has said that Israel is expected to be the first country in the world to vaccinate its population against COVID-19.
Japan has procurement deals with half of the companies leading the COVID-19 vaccine development race, according to GlobalData.